 | • レポートコード：MRC2304A187 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、253ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査レポートでは、2021年に7,006.17百万ドルであった世界の次世代がん診断市場規模が2022年に8,638.56百万ドルへと拡大、更に2027年までにCAGR 23.47％で成長して24,830.48百万ドルに達すると予測しています。当書は、次世代がん診断の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別分析（DNAマイクロアレイ、ラボオンチップ＆逆転写酵素PCR、次世代シーケンシング、タンパク質マイクロアレイ、qPCR＆マルチプレックス）、がん種類別分析（乳がん、子宮頸がん、大腸がん、肺がん）、機能別分析（がん検診、コンパニオン診断、予知、リスク分析、治療モニタリング）、用途別分析（バイオマーカー開発、CTC分析、エピジェネティック解析、遺伝子解析、プロテオーム解析）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの構成でまとめています。なお、当書には、Abbott Laboratories、Adaptive Biotechnologies Inc.、Agendia Nv、Agilent Technologies, Inc、Akadeum Life Sciences、Almac Group、Ambry Genetics、Becton, Dickinson And Co.、Biological Dynamics Inc.、Castle Biosciences Inc.、Danaher Corporationなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の次世代がん診断市場規模：技術別 - DNAマイクロアレイの市場規模 - ラボオンチップ＆逆転写酵素PCRの市場規模 - 次世代シーケンシングの市場規模 - タンパク質マイクロアレイの市場規模 - qPCR＆マルチプレックスの市場規模 ・世界の次世代がん診断市場規模：がん種類別 - 乳がん診断の市場規模 - 子宮頸がん診断の市場規模 - 大腸がん診断の市場規模 - 肺がん診断の市場規模 ・世界の次世代がん診断市場規模：機能別 - がん検診の市場規模 - コンパニオン診断の市場規模 - 予知の市場規模 - リスク分析の市場規模 - 治療モニタリングの市場規模 ・世界の次世代がん診断市場規模：用途別 - バイオマーカー開発における市場規模 - CTC分析における市場規模 - エピジェネティック解析における市場規模 - 遺伝子解析における市場規模 - プロテオーム解析における市場規模 ・世界の次世代がん診断市場規模：地域別 - 南北アメリカの次世代がん診断市場規模 アメリカの次世代がん診断市場規模 カナダの次世代がん診断市場規模 ブラジルの次世代がん診断市場規模 ... - アジア太平洋の次世代がん診断市場規模 日本の次世代がん診断市場規模 中国の次世代がん診断市場規模 インドの次世代がん診断市場規模 韓国の次世代がん診断市場規模 台湾の次世代がん診断市場規模 ... - ヨーロッパ/中東/アフリカの次世代がん診断市場規模 イギリスの次世代がん診断市場規模 ドイツの次世代がん診断市場規模 フランスの次世代がん診断市場規模 ロシアの次世代がん診断市場規模 ... - その他地域の次世代がん診断市場規模 ・競争状況 ・企業情報 |
The Global Next Generation Cancer Diagnostics Market size was estimated at USD 7,006.17 million in 2021 and expected to reach USD 8,638.56 million in 2022, and is projected to grow at a CAGR 23.47% to reach USD 24,830.48 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Next Generation Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technology, the market was studied across DNA Microarrays, Lab-on- a- chip & Reverse Transcriptase-PCR, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing.
Based on Cancer Type, the market was studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, and Lung Cancer.
Based on Function, the market was studied across Cancer Screening, Companion Diagnostics, Prognostics, Risk Analysis, and Therapeutic Monitoring.
Based on Application, the market was studied across Biomarker Development, CTC Analysis, Epigenetic Analysis, Genetic Analysis, and Proteomic Analysis.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Next Generation Cancer Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Next Generation Cancer Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Next Generation Cancer Diagnostics Market, including Abbott Laboratories, Adaptive Biotechnologies Inc., Agendia Nv, Agilent Technologies, Inc, Akadeum Life Sciences, Almac Group, Ambry Genetics, Becton, Dickinson And Co., Biological Dynamics Inc., Castle Biosciences Inc., Danaher Corporation, Exosome Diagnostics, Inc., F. Hoffmann-La Roche Ltd, GE Healthcare, Genomic Health, Inc., Hologic, Inc, Illumina, Inc., Janssen Global Services, LLC, Koninklijke Philips N.V., Myriad Genetics, Inc., Novartis AG, Opko Health, Inc., Perkin Elmer, Inc., Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Next Generation Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Next Generation Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Next Generation Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Next Generation Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Next Generation Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the Global Next Generation Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Next Generation Cancer Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of oncology diseases
5.1.1.2. Significantly decreasing cost of genetic sequencing
5.1.1.3. Benefits of cluster chip technology and applications of CTC in cancer management
5.1.2. Restraints
5.1.2.1. Need for expensive laboratory set-up
5.1.2.2. Insufficient reimbursement policies for innovative technologies
5.1.3. Opportunities
5.1.3.1. Government support in a number of research projects in oncology and preventative diagnosis
5.1.3.2. Potential CTC enumeration sectors to monitor tumorigenesis
5.1.4. Challenges
5.1.4.1. Shortage of helium and increased cost of diagnostic imaging systems
5.2. Cumulative Impact of COVID-19
6. Next Generation Cancer Diagnostics Market, by Technology
6.1. Introduction
6.2. DNA Microarrays
6.3. Lab-on- a- chip & Reverse Transcriptase-PCR
6.4. Next Generation Sequencing
6.5. Protein Microarrays
6.6. qPCR & Multiplexing
7. Next Generation Cancer Diagnostics Market, by Cancer Type
7.1. Introduction
7.2. Breast Cancer
7.3. Cervical Cancer
7.4. Colorectal Cancer
7.5. Lung Cancer
8. Next Generation Cancer Diagnostics Market, by Function
8.1. Introduction
8.2. Cancer Screening
8.3. Companion Diagnostics
8.4. Prognostics
8.5. Risk Analysis
8.6. Therapeutic Monitoring
9. Next Generation Cancer Diagnostics Market, by Application
9.1. Introduction
9.2. Biomarker Development
9.3. CTC Analysis
9.4. Epigenetic Analysis
9.5. Genetic Analysis
9.6. Proteomic Analysis
10. Americas Next Generation Cancer Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Next Generation Cancer Diagnostics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Next Generation Cancer Diagnostics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Adaptive Biotechnologies Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Agendia Nv
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Agilent Technologies, Inc
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Akadeum Life Sciences
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Almac Group
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Ambry Genetics
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Becton, Dickinson And Co.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Biological Dynamics Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Castle Biosciences Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Danaher Corporation
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Exosome Diagnostics, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. F. Hoffmann-La Roche Ltd
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. GE Healthcare
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Genomic Health, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Hologic, Inc
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Illumina, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Janssen Global Services, LLC
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Koninklijke Philips N.V.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Myriad Genetics, Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Novartis AG
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Opko Health, Inc.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Perkin Elmer, Inc.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Qiagen N.V.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Sysmex Corporation
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. Thermo Fisher Scientific, Inc.
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing